The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease
暂无分享,去创建一个
Nathan C. Sheffield | P. Meltzer | P. Sorensen | M. Ladanyi | A. Sweet-Cordero | J. Mora | K. Stegmaier | U. Dirksen | O. Delattre | B. Schäfer | A. Üren | A. Shelat | F. Tirode | P. Houghton | K. Iljin | A. Zinovyev | H. Kovar | S. Lessnick | E. de Álava | K. Tsafou | J. Ludwig | Elizabeth Stewart | J. Toretsky | R. Moriggl | L. Helman | S. Burdach | P. Grohar | K. Scotlandi | E. Lawlor | Takuro Nakamura | K. Szuhai | C. Rossig | J. Amatruda | M. Metzler | T. G. Grünewald | F. Cidre-Aranaz | F. Redini | E. Korsching | Keri L Schadler | E. Snaar-Jagalska | E. Brunet | Ò. M. Tirado | G. Richter | W. van der Ent | T. Papamarkou | Branka Radic Sarikas | Ewa Snaar-Jagalska | Ewa B. Snaar-Jagalska
[1] U. Dirksen,et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] B. Weir,et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma , 2015, Oncotarget.
[3] A. Mikos,et al. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma , 2015, Proceedings of the National Academy of Sciences.
[4] S. Chanock,et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite , 2015, Nature Genetics.
[5] U. Dirksen,et al. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma , 2015, Clinical Cancer Research.
[6] M. Simon,et al. Oncogenes strike a balance between cellular growth and homeostasis. , 2015, Seminars in cell & developmental biology.
[7] J. Mora,et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2015, Oncotarget.
[8] P. Sorensen,et al. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.
[9] Andrei Zinovyev,et al. Predicting genetic interactions from Boolean models of biological networks , 2015, bioRxiv.
[10] Emmanuel Barillot,et al. Predicting genetic interactions from Boolean models of biological networks. , 2015, Integrative biology : quantitative biosciences from nano to macro.
[11] P. Sorensen,et al. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1 , 2015, The Journal of cell biology.
[12] P. Meltzer,et al. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma , 2015, Clinical Cancer Research.
[13] Cathy H. Wu,et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing , 2015, Proceedings of the National Academy of Sciences.
[14] Nathan C. Sheffield,et al. Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1 , 2015, Cell reports.
[15] K. Nakao,et al. Somatic chromosomal translocation between Ewsr1 and Fli1 loci leads to dilated cardiomyopathy in a mouse model , 2015, Scientific Reports.
[16] Marcus R. Breese,et al. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. , 2014, The Journal of clinical investigation.
[17] Martin J. Aryee,et al. EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma , 2014 .
[18] Li Ding,et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.
[19] A. McKenna,et al. The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.
[20] Peter E. Wright,et al. Assemblages: Functional units formed by cellular phase separation , 2014, The Journal of cell biology.
[21] Jun S. Wei,et al. The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.
[22] K. Igarashi,et al. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. , 2014, The Journal of clinical investigation.
[23] M. Beckerle,et al. Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth , 2014, Clinical Cancer Research.
[24] H. Kovar,et al. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs , 2014, Epigenetics.
[25] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[26] Y. Pommier,et al. Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth , 2013, Clinical Cancer Research.
[27] S. Lessnick,et al. Children's Oncology Group's 2013 blueprint for research: Bone tumors , 2013, Pediatric blood & cancer.
[28] P. Meltzer,et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. , 2013, Cancer discovery.
[29] M. Krook,et al. LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling , 2013, Front. Oncol..
[30] P. Sorensen,et al. The First European Interdisciplinary Ewing Sarcoma Research Summit , 2012, Front. Oncol..
[31] Arul M Chinnaiyan,et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.
[32] F. Clavel-Chapelon,et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma , 2012, Nature Genetics.
[33] Aaron R Cooper,et al. Modeling Initiation of Ewing Sarcoma in Human Neural Crest Cells , 2011, PloS one.
[34] M. Goodman,et al. Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades: Surveillance Epidemiology and End Results Data , 2008, Journal of pediatric hematology/oncology.
[35] O. Delattre,et al. Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.
[36] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.